Aigen Investment Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Aigen Investment Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,672	Closed	-$394K	–	1027
2023 Q1	$394K	Buy	+3,672	New	+$423K	0.05%	361
2022 Q4	–	Sell	-4,206	Closed	-$248K	–	833
2022 Q3	$248K	Buy	+4,206	New	+$192K	0.04%	455

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Aigen Investment Management's RXDX Position: Q2 2023 in Review

Aigen Investment Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 3,672 shares — an estimated $394K sold.

Aigen Investment Management first reported a position in RXDX in Q3 2022 and held it in 2 quarters. The position peaked at $394K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Aigen Investment Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Aigen Investment Management sold 3,672 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $394K.
Aigen Investment Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 2 quarters.
Aigen Investment Management's Prometheus Biosciences, Inc. Common Stock position peaked at $394K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Aigen Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.